MARKET

TVRD

TVRD

Tvardi Therapeutics Inc
NASDAQ
3.720
-0.060
-1.59%
After Hours: 3.720 0 0.00% 16:10 02/12 EST
OPEN
3.820
PREV CLOSE
3.780
HIGH
3.825
LOW
3.610
VOLUME
39.38K
TURNOVER
--
52 WEEK HIGH
43.65
52 WEEK LOW
3.500
MARKET CAP
34.90M
P/E (TTM)
-0.4452
1D
5D
1M
3M
1Y
5Y
1D
Tvardi Therapeutics: Positive Phase 2 IPF Signal and Next-Gen STAT3 Pipeline Position Shares as a Buy Ahead of 2026 Catalysts
TipRanks · 6h ago
Tvardi Therapeutics to Present at Major Healthcare Investor Conferences
Reuters · 14h ago
Weekly Report: what happened at TVRD last week (0202-0206)?
Weekly Report · 3d ago
Tvardi Therapeutics upgraded to Buy from Neutral at Lucid Capital
TipRanks · 02/04 11:11
Weekly Report: what happened at TVRD last week (0126-0130)?
Weekly Report · 02/02 10:27
Analysts Are Bullish on These Healthcare Stocks: Capricor Therapeutics (CAPR), Tvardi Therapeutics (TVRD)
TipRanks · 01/29 13:40
Weekly Report: what happened at TVRD last week (0119-0123)?
Weekly Report · 01/26 10:26
Analysts Offer Insights on Healthcare Companies: Aclaris Therapeutics (ACRS) and Tvardi Therapeutics (TVRD)
TipRanks · 01/21 11:30
More
About TVRD
Tvardi Therapeutics, Inc., formerly Cara Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting (STAT3) to treat fibrosis-driven diseases with significant unmet need. STAT3 is a central mediator across critical fibrotic signaling pathways that drive uncontrolled deposition, proliferation, survival and immune suppression. STAT3 is also positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. Its product candidate, TTI-101, is in Phase 2 clinical development for the treatment of fibrosis-driven diseases, with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is an oral, small-molecule, which is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.

Webull offers Tvardi Therapeutics Inc stock information, including NASDAQ: TVRD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TVRD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TVRD stock methods without spending real money on the virtual paper trading platform.